PSTX — Poseida Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $194.91m
- $41.30m
- $64.70m
- 15
- 21
- 42
- 16
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -86.5 | -130 | -125 | -64 | -123 |
Depreciation | |||||
Non-Cash Items | 11.3 | 8.24 | -2.29 | 18.3 | 11.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 9.47 | 5.62 | 20.2 | 13.7 | 14.1 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -64.5 | -113 | -103 | -26.8 | -92.2 |
Capital Expenditures | -5.16 | -16.9 | -2.63 | -3.92 | -3.07 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -37.3 | -188 | 225 | -199 | 42.2 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -42.5 | -204 | 222 | -203 | 39.1 |
Financing Cash Flow Items | 4.59 | 3.83 | 0 | -1.45 | -0.494 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 164 | 314 | 2.52 | 105 | 16.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 57.4 | -3.82 | 122 | -125 | -36.9 |